Search Results - "VanDevanter, Donald R"

Decade-long bacterial community dynamics in cystic fibrosis airways by Zhao, Jiangchao, Schloss, Patrick D, Kalikin, Linda M, Carmody, Lisa A, Foster, Bridget K, Petrosino, Joseph F, Cavalcoli, James D, VanDevanter, Donald R, Murray, Susan, Li, Jun Z, Young, Vincent B, LiPuma, John J

“…The structure and dynamics of bacterial communities in the airways of persons with cystic fibrosis (CF) remain largely unknown. We characterized the bacterial…”
Get full text

Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis by Carmody, Lisa A, Caverly, Lindsay J, Foster, Bridget K, Rogers, Mary A M, Kalikin, Linda M, Simon, Richard H, VanDevanter, Donald R, LiPuma, John J

“…Bacteria that infect the airways of persons with cystic fibrosis (CF) include a group of well-described opportunistic pathogens as well as numerous, mainly…”
Get full text

Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment by VanDevanter, Donald R, Kahle, Jennifer S, O’Sullivan, Amy K, Sikirica, Slaven, Hodgkins, Paul S

“…Abstract Background Studies have described illness associated with cystic fibrosis (CF) early in life, but there is no comprehensive accounting of the…”
Get full text

Improvements in Lung Function and Height among Cohorts of 6-Year-Olds with Cystic Fibrosis from 1994 to 2012 by VanDevanter, Donald R., PhD, Pasta, David J., MS, Konstan, Michael W., MD

“…Objective To characterize spirometry and height changes in cohorts of 6-year-old children with cystic fibrosis (CF). Study design Global Lung Initiative forced…”
Get full text

Assessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbations by VanDevanter, Donald R, O'Riordan, Mary A, Blumer, Jeffrey L, Konstan, Michael W

“…Cystic Fibrosis (CF) is a life-shortening genetic disease in which ~80% of deaths result from loss of lung function linked to inflammation due to chronic…”
Get full text

Challenges to the optimisation of cystic fibrosis exacerbation treatment outcomes by Goss, Christopher H, VanDevanter, Donald R

Get more information

The march towards CFTR modulator access for all people with CF: The end of the beginning by VanDevanter, Donald R

Get full text

Retracing changes in cystic fibrosis understanding and management over the past twenty years by Ratjen, Felix, VanDevanter, Donald R.

Get full text

Clinical applications of pulmonary delivery of antibiotics by Flume, Patrick A., VanDevanter, Donald R.

“…The treatment of infection typically involves administration of antibiotics by a systemic route, such as intravenous or oral. However, pulmonary infections can…”
Get full text

Re-examining baseline lung function recovery following IV-treated pulmonary exacerbations by Heltshe, Sonya L., Russell, Renee, VanDevanter, Donald R., Sanders, Don B.

“…•Many researchers use ‘before and after’ approaches to study lung function recovery around a pulmonary exacerbation.•This method lacks comparators and ascribes…”
Get full text

Leveraging early markers of cystic fibrosis structural lung disease to improve outcomes by Flume, Patrick A, VanDevanter, Donald R

Get full text

CFTR modulator theratyping: Current status, gaps and future directions by Clancy, John Paul, Cotton, Calvin U., Donaldson, Scott H., Solomon, George M., VanDevanter, Donald R., Boyle, Michael P., Gentzsch, Martina, Nick, Jerry A., Illek, Beate, Wallenburg, John C., Sorscher, Eric J., Amaral, Margarida D., Beekman, Jeffrey M., Naren, Anjaparavanda P., Bridges, Robert J., Thomas, Philip J., Cutting, Garry, Rowe, Steven, Durmowicz, Anthony G., Mense, Martin, Boeck, Kris D., Skach, William, Penland, Christopher, Joseloff, Elizabeth, Bihler, Hermann, Mahoney, John, Borowitz, Drucy, Tuggle, Katherine L.

“…New drugs that improve the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein with discreet disease-causing variants have been…”
Get full text

Antimicrobial susceptibility testing (AST) and associated clinical outcomes in individuals with cystic fibrosis: A systematic review by Somayaji, Ranjani, Parkins, Michael D., Shah, Anand, Martiniano, Stacey L., Tunney, Michael M., Kahle, Jennifer S., Waters, Valerie J., Elborn, J. Stuart, Bell, Scott C., Flume, Patrick A., VanDevanter, Donald R.

“…Antimicrobial susceptibility testing (AST) is a cornerstone of infection management. Cystic fibrosis (CF) treatment guidelines recommend AST to select…”
Get full text

Reconciling Antimicrobial Susceptibility Testing and Clinical Response in Antimicrobial Treatment of Chronic Cystic Fibrosis Lung Infections by Waters, Valerie J, Kidd, Timothy J, Canton, Rafael, Ekkelenkamp, Miquel B, Johansen, Helle Krogh, LiPuma, John J, Bell, Scott C, Elborn, J Stuart, Flume, Patrick A, VanDevanter, Donald R, Gilligan, Peter

“…Median cystic fibrosis (CF) survival has increased dramatically over time due to several factors, including greater availability and use of antimicrobial…”
Get full text

Innovating cystic fibrosis clinical trial designs in an era of successful standard of care therapies by VanDevanter, Donald R, Mayer-Hamblett, Nicole

“…Evolving cystic fibrosis 'standards of care' have influenced recent cystic fibrosis clinical trial designs for new therapies; care additions/improvements will…”
Get full text

Corrigendum to FEV1 Variability Helps Identify Patients with Cystic Fibrosis at Risk of Greater Loss of Lung Function [The Journal of Pediatrics (2016) 116–121] by Morgan, Wayne J., VanDevanter, Donald R., Pasta, David J., Foreman, Aimee J., Wagener, Jeffrey S., Konstan, Michael W.

Get full text

Evaluating assumptions of definition-based pulmonary exacerbation endpoints in cystic fibrosis clinical trials by VanDevanter, Donald R., Hamblett, Nicole Mayer, Simon, Noah, McIntosh, Joseph, Konstan, Michael W.

“…•Pulmonary exacerbation difference is an important clinical trial efficacy endpoint.•Regulators have stressed use of Fuchs criteria-based exacerbation…”
Get full text

Developing Inhaled Antibiotics in Cystic Fibrosis: Current Challenges and Opportunities by Nichols, Dave P, Durmowicz, Anthony G, Field, Ann, Flume, Patrick A, VanDevanter, Donald R, Mayer-Hamblett, Nicole

“…P. aeruginosa, in particular, is linked to greater airway inflammation and overall decline in health (4, 5). Because of this, strategies to administer…”
Get full text

Adjunctive Systemic Corticosteroids for Pulmonary Exacerbations of Cystic Fibrosis by McElvaney, Oliver J, Heltshe, Sonya L, Odem-Davis, Katherine, West, Natalie E, Sanders, Don B, Fogarty, Barbra, VanDevanter, Donald R, Flume, Patrick A, Goss, Christopher H

“…Pulmonary exacerbations (PEx) remain the most common cause of morbidity, recurrent hospitalization, and diminished survival in people with cystic fibrosis…”
Get more information

Defining antimicrobial resistance in cystic fibrosis by Kidd, Timothy J., Canton, Rafael, Ekkelenkamp, Miquel, Johansen, Helle Krogh, Gilligan, Peter, LiPuma, John J., Bell, Scott C., Elborn, J. Stuart, Flume, Patrick A., VanDevanter, Donald R., Waters, Valerie J.

“…Antimicrobial resistance (AMR) can present significant challenges in the treatment of cystic fibrosis (CF) lung infections. In CF and other chronic diseases,…”
Get full text